Transformative Therapies | Targeting Cancer

Revolutionary science focused on patient outcomes

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops, and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives.

ADCETRIS® (brentuximab vedotin) and PADCEV™ (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA™ (tucatinib) is a small molecule tyrosine kinase inhibitor and is approved for certain HER2-positive metastatic breast cancers.

The company has a pipeline of novel targeted therapies at various stages of preclinical and clinical testing, as well as continuing development of our approved medicines. We also are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.